RxDoctor Payments Data

Kingsley Annan, MD

Interventional Cardiology · Kokomo, INNPI 1548233158

Payments from drug & device makers

$1,456in general payments, 2019–2025

Across 66 payments — averaging $22.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$453
  • Johnson & Johnson$332
  • Boston Scientific$161
  • Novartis$88
  • Actelion Pharmaceuticals US, Inc.$74
  • Gilead$72
  • plus $277 from 8 others

What the payments were for

  • Food & beverage$1,44499%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,456 in reported general payments places this provider in the 15th percentile of 170 interventional cardiology providers in Indiana.

See all interventional cardiology providers in Indiana

Medicare billing

Part B allowed, 2024
$140,429
Medicare patients
982
Services billed
1,779

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban485$612,976
XareltoRivaroxaban195$261,742
EntrestoSacubitril/Valsartan104$153,458
MultaqDronedarone Hcl36$51,045
JardianceEmpagliflozin24$39,800
Repatha SureclickEvolocumab14$20,836
Propafenone Hcl ErPropafenone Hcl77$18,134
BrilintaTicagrelor22$17,377
Dabigatran EtexilateDabigatran Etexilate Mesylate48$13,805
Rosuvastatin Calcium591$10,759
Metoprolol Succinate663$9,716
Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med161$8,882
Diltiazem 24hr Er (Cd)Diltiazem Hcl209$7,593
Potassium Chloride307$5,615
Ranolazine ErRanolazine38$5,512

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$45$612,976485 claims
Johnson & JohnsonXarelto$332$261,742195 claims
NovartisEntresto$88$153,458104 claims
Sanofi-aventis U.S. LLCMultaq$39$51,04536 claims
AstraZenecaBrilinta$22$17,37722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 170 interventional cardiology providers in Indiana.

Other interventional cardiology in Kokomo

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →